WO2013001372A3 - Methods and compositions for inhibition of activation of regulatory t cells - Google Patents

Methods and compositions for inhibition of activation of regulatory t cells Download PDF

Info

Publication number
WO2013001372A3
WO2013001372A3 PCT/IB2012/001733 IB2012001733W WO2013001372A3 WO 2013001372 A3 WO2013001372 A3 WO 2013001372A3 IB 2012001733 W IB2012001733 W IB 2012001733W WO 2013001372 A3 WO2013001372 A3 WO 2013001372A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
methods
activation
inhibition
compositions
Prior art date
Application number
PCT/IB2012/001733
Other languages
French (fr)
Other versions
WO2013001372A2 (en
Inventor
Kjetil Tasken
Maria Elisabeth KALLAND
Knut Martin TORGERSEN
Nikolaus G. OBERPRIELER
Torkel Vang
Original Assignee
University Of Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Oslo filed Critical University Of Oslo
Publication of WO2013001372A2 publication Critical patent/WO2013001372A2/en
Publication of WO2013001372A3 publication Critical patent/WO2013001372A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to human regulatory T cells (Tregs). In particular, the present invention relates to compositions and methods for inhibiting activation of Tregs and to methods of inhibiting excessive immunosuppressive activity in a cell, comprising contacting a cell with an inhibitor selected from the group consisting of MEK, ERK, and AKT1/2 inhibitors and combinations thereof, wherein the contacting results in inhibition of activation of resting human regulatory T cells (rTregs) to active Tregs (aTregs). In other embodiments, the invention provides for the use of an inhibitor selected from the group consisting of MEK, ERK, and AKT1/2 inhibitors and combinations thereof to treat a chronic infectious disease in a subject
PCT/IB2012/001733 2011-06-30 2012-06-29 Methods and compositions for inhibition of activation of regulatory t cells WO2013001372A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161502989P 2011-06-30 2011-06-30
US61/502,989 2011-06-30
US201161531283P 2011-09-06 2011-09-06
US61/531,283 2011-09-06

Publications (2)

Publication Number Publication Date
WO2013001372A2 WO2013001372A2 (en) 2013-01-03
WO2013001372A3 true WO2013001372A3 (en) 2013-04-25

Family

ID=46881107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/001733 WO2013001372A2 (en) 2011-06-30 2012-06-29 Methods and compositions for inhibition of activation of regulatory t cells

Country Status (1)

Country Link
WO (1) WO2013001372A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5511680B2 (en) 2007-12-19 2014-06-04 キャンサー・リサーチ・テクノロジー・リミテッド Pyrido [2,3-B] pyrazine-8-substituted compounds and uses thereof
PL2531502T3 (en) 2010-02-01 2014-08-29 Cancer Research Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2015066439A2 (en) * 2013-11-01 2015-05-07 Foundation Medicine, Inc. Methods of treating hematological malignancies
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
KR101497146B1 (en) * 2014-01-29 2015-03-03 강원대학교산학협력단 Composition for supressing metastasis of cancer cell
GB201410741D0 (en) * 2014-06-17 2014-07-30 Babraham Inst And University Of Birmingham The Novel diagnostic and therapeutic method
CN110151763A (en) * 2019-06-26 2019-08-23 深圳市第三人民医院 It examines than treating the application in tubercular drugs as preparation for Buddhist nun
CN110664811B (en) * 2019-09-18 2022-11-29 深圳市第三人民医院 Application of afatinib in anti-mycobacterium tuberculosis drugs
WO2021168283A1 (en) * 2020-02-19 2021-08-26 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087941A1 (en) * 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
WO2008125820A1 (en) * 2007-04-13 2008-10-23 Astrazeneca Ab Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
WO2010105110A1 (en) * 2009-03-11 2010-09-16 Ardea Biosciences, Inc. Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
WO2011070030A1 (en) * 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
WO2012059041A1 (en) * 2010-11-02 2012-05-10 Centaurus Biopharma Co., Ltd. Novel 6-arylamino pyridone carboxamide as mek inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE336587T1 (en) 1994-06-10 2006-09-15 Genvec Inc ADENOVIRUS VECTOR SYSTEMS AND CELL LINES
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU6261696A (en) 1995-06-05 1996-12-24 Trustees Of The University Of Pennsylvania, The A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
DE69633565T3 (en) 1995-06-15 2013-01-17 Crucell Holland B.V. PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRES, FOR USE IN GENE THERAPY
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
AU756549B2 (en) 1997-07-11 2003-01-16 Crucell Holland B.V. Interleukin-3 gene therapy for cancer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
MXPA01001727A (en) 1998-08-14 2001-11-27 Aventis Pharm Prod Inc Adenovirus formulations for gene therapy.
CA2341061A1 (en) 1998-08-27 2000-03-09 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
US7060436B2 (en) 2000-06-17 2006-06-13 Third Wave Technologies, Inc. Nucleic acid accessible hybridization sites
TR200401292T3 (en) 2000-12-01 2004-07-21 Max@Planck@Gesellschaft�Zur�F�Rderung�Der�Wissenschaften the rnaágirişimineáyoláaçanáküçükárnaámolekül
CA2921821A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
JP2005517450A (en) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド RNA interference-mediated target discovery and target evaluation using short interfering nucleic acids (siNA)
EP1546397A4 (en) 2002-09-27 2007-10-31 Cold Spring Harbor Lab Cell-based rna interference and related methods and compositions
WO2005038054A1 (en) 2003-10-20 2005-04-28 Zicai Liang METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES
GB0327726D0 (en) 2003-11-28 2003-12-31 Isis Innovation Method
AU2005316458B2 (en) 2004-12-17 2011-04-07 Beth Israel Deaconess Medical Center Compositions for bacterial mediated gene silencing and methods of using same
EP2089521A1 (en) 2006-02-08 2009-08-19 Ercole Biotech, Inc. Soluble tnf receptors and their use in treatment of disease
US20100062994A1 (en) 2006-07-14 2010-03-11 Santaris Pharma A/S Adenosine Receptor Antagonists
CA2666191C (en) 2006-10-09 2017-07-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pcsk9

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087941A1 (en) * 2002-02-15 2004-10-14 The General Hospital Corporation Map-kinase inhibitors as regulators of tumor-associated antigen expression
WO2008125820A1 (en) * 2007-04-13 2008-10-23 Astrazeneca Ab Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
WO2010105110A1 (en) * 2009-03-11 2010-09-16 Ardea Biosciences, Inc. Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
WO2011070030A1 (en) * 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
WO2012059041A1 (en) * 2010-11-02 2012-05-10 Centaurus Biopharma Co., Ltd. Novel 6-arylamino pyridone carboxamide as mek inhibitors

Also Published As

Publication number Publication date
WO2013001372A2 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
WO2013001372A3 (en) Methods and compositions for inhibition of activation of regulatory t cells
WO2011127070A3 (en) IRE-1α INHIBITORS
EP3354640A3 (en) Mif inhibitors and their uses
WO2013188813A3 (en) Novel therapeutics for brain cancer
WO2011113798A3 (en) Inhibitors of semicarabazide - sensitive amine oxidase
MX2013011721A (en) Methods for treating conditions associated with masp-2 dependent complement activation.
WO2008019871A3 (en) Novel salts of the active substance rasagiline
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
WO2012158624A3 (en) Inhibitors of mitochondrial fission and methods of use thereof
WO2011126250A3 (en) Composition containing pde5 inhibitor for relieving skin wrinkles
WO2009079452A3 (en) Treatment and prevention of hiv infection
WO2012158672A3 (en) Compounds for use in treatment of mucositis
EP2594270A3 (en) The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
MX2014016121A (en) Agent for preventing deterioration in vascular endothelial function or improving vascular endothelial function.
WO2011149288A3 (en) Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
WO2012074725A3 (en) Immunomodulatory methods and systems for treatment and/or prevention of hypertension
WO2013037943A8 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
SG195170A1 (en) Methods of treating or preventing rheumatic disease
WO2010053435A3 (en) Compounds and methods for the treatment of inflammatory diseases of the cns
WO2011116245A3 (en) Methods of treating inflammation
WO2011021818A3 (en) Composition for proliferating epidermal keratinocyte stem cells
WO2012074676A3 (en) Glp-1 agonists, dpp-4 inhibitors, compositions, and uses related thereto
WO2010075086A3 (en) Pyrrolidinone inhibitors of pde-4

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12761809

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12761809

Country of ref document: EP

Kind code of ref document: A2